Predictive models (Antibody Prevalence in Epilepsy and Encephalopathy [APE2] and Response to Immunotherapy in Epilepsy and Encephalopathy [RITE2] scores) based on clinical features and initial neurological assessment may be utilized for selection of cases for autoimmune epilepsy evaluation and management.

Antibody Prevalence in Epilepsy 2 (APE2) and Response to Immunotherapy in Epilepsy 2 (RITE2) scores were developed recently to identify patients who may be seropositive for serum central nervous system (CNS) specific antibodies (Ab) and may benefit from immunotherapy (Dubey et …

Sensitivity and specificity of a RITE score ≥7 to predict favorable seizure outcome were 87.5% and 83.8%, respectively. Significance: APE and RITE scores can aid diagnosis, treatment, and prognostication of autoimmune epilepsy.

The APE 2 -CHN and RITE 2 -CHN scores may be useful screening tools in predicting positive antibody findings and prognosis of suspected autoimmune seizures or associated epilepsy in the Chinese population.

2020年10月1日 · In this study, we modified and validated scoring systems based on the Antibody-Prevalence in Epilepsy and Encephalopathy (APE 2) and Responsive to immunotherapy in Epilepsy and Encephalopathy (RITE 2) scores [20] as predictive models for the presence of neural-specific antibodies and response to immunotherapy in epilepsy with unknown etiology.

2022年12月5日 · The APE2 score = 4 to predict positive serum Ab had a sensitivity of 92.7% and specificity of 6.7%. The RITE2 score = 7 to predict seizure responsiveness to immunotherapy had a sensitivity of 92.9% and specificity of 60%.

2022年7月30日 · This retrospective cohort study intended to assess the performance of a pediatric adaptation of the Response to Immunotherapy in Epilepsy (RITE 2) score: P-RITE 2 score and Antibody Prevalence in Epilepsy (APE 2) score: P …

In this research, based on heuristic optimization algorithms, three new strategies are developed for Aerodynamic Parameters Estimation (APE) of one pair ON-OFF actuator rolling airframe. In the 1st...

Antibody Prevalence in Epilepsy 2 (APE2) and Response to Immunotherapy in Epilepsy 2 (RITE2) scores were developed recently to identify patients who may be seropositive for serum central nervous system (CNS) specific antibodies (Ab) and may benefit from immunotherapy (Dubey et …

The APE2 score was significantly higher in patients with antibody positivity (median 6, range 2–11) compared with antibody negative cases (median 4, range 1–9) (P = 0.038 Mann-Whitney). An APE2 score ≥4 showed a sensitivity of 61.5% and specificity of 40% for the presence of neuronal antibodies and a sensitivity of 78.5% with a ...